The short answer
Two systematic reviews published in 2025 (Sarkar in the International Journal of Dermatology and Alzahrani in Cureus) examined glutathione as a skin-lightening agent. The literature exists and has been formally reviewed, and safety concerns about intravenous administration are a recurring theme in it.
Key facts
- Sarkar 2025
- Int J Dermatol, systematic review
- Alzahrani 2025
- Cureus, safety and efficacy review
- Dilokthornsakul 2019
- J Cosmet Dermatol, clinical effect
- Proposed mechanism
- Melanin synthesis pathway
- Recurring concern
- Intravenous administration safety
- Marketing authorisation
- None for this purpose
Why a review-level literature exists
Glutathione for skin lightening has been used widely enough, in enough places, to generate a body of clinical work worth reviewing systematically. Two such reviews appeared in 2025: Sarkar and colleagues in the International Journal of Dermatology, covering skin-lightening and melasma, and Alzahrani and colleagues in Cureus on safety and efficacy. Dilokthornsakul and colleagues had reviewed clinical effects on skin colour in 2019.
The proposed mechanism
Melanin synthesis proceeds through an enzymatic pathway, and glutathione is described as interacting with it, both directly and through the shift from one melanin type toward another. This is a plausible biochemical rationale rather than a demonstrated mode of action in skin, and the reviews are the place to see how well the clinical data supports it.
Research material referenced
Glutathione 1500mg, third-party HPLC tested
The safety question the reviews keep raising
Intravenous administration for cosmetic purposes has attracted specific regulatory attention in several jurisdictions, and safety is a stated focus of the 2025 Cureus review rather than an afterthought. When a review of a cosmetic intervention foregrounds safety, that is itself informative about the state of the practice.
What the review-level evidence is worth
Systematic reviews are stronger than individual studies because they assess the whole body of work including its quality. Two appearing in the same year suggests both continuing interest and unresolved questions, since a settled matter does not generate simultaneous independent reviews.
What is being said and not said here
Reportable: that this literature exists, that it has been systematically reviewed in 2025, and that safety of intravenous use is a recurring concern within it. Not sayable, and not said: that glutathione lightens skin, treats melasma, or should be used for any cosmetic purpose. Glutathione holds no marketing authorisation for any of this.
Why this is the category's compliance pressure point
The commercial interest in glutathione is largely cosmetic, which means the gap between describing a literature and making a claim is narrower here than anywhere else in the catalogue. Material supplied here is for laboratory research and is not a cosmetic product.
Frequently asked questions
Is there real research on glutathione and skin?
Yes. There is enough for two systematic reviews in 2025, in the International Journal of Dermatology and Cureus, plus a 2019 review in the Journal of Cosmetic Dermatology.
What is the concern with intravenous use?
Safety, which is a stated focus of the 2025 Cureus review and has attracted regulatory attention in several jurisdictions.
Is glutathione approved for skin lightening?
No. It holds no marketing authorisation for that or any other purpose.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedSarkar R et al., Glutathione as a skin-lightening agent and in melasma: a systematic review. Int J Dermatol 2025 (PMID 39444151)pubmed.ncbi.nlm.nih.gov
- PubMedAlzahrani TF et al., Safety and efficacy of glutathione supplementation for skin lightening. Cureus 2025 (PMID 40013212)pubmed.ncbi.nlm.nih.gov
- PubMedDilokthornsakul W et al., Clinical effect of glutathione on skin color. J Cosmet Dermatol 2019 (PMID 30895708)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More Glutathione articles
- Glutathione Storage and the Oxidation ProblemThe one compound in this catalogue where disulfide chemistry is a daily practical issue. Air converts GSH to GSSG, and purity does not capture it.
- Glutathione in the Published LiteratureOne of the most-studied small molecules in biology, with randomised trials and 2025 systematic reviews. How to navigate a literature this large.
- Glutathione Regulatory StatusNo marketing authorisation as a medicine. Why the cosmetic use has drawn specific regulatory attention in several jurisdictions.
- Glutathione Proposed as a Carrier, Not Just a BufferOrlowski and Meister named the gamma-glutamyl cycle in 1970 and proposed that glutathione serves a carrier function in amino acid transport.
- A Routine Liver Test That Measures a Glutathione EnzymeGamma-glutamyl transferase appears on ordinary liver blood panels. It is the enzyme that cleaves glutathione's gamma bond.